Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 128 participants.
Also called NCT04169269
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 128 participants
- Sponsor
- Florida Orthopaedic Institute
- Registry
-
NCT04169269
-
- Other papers using this trial's data
- A Prospective Randomized Controlled Trial Comparing Enoxaparin & Rivaroxaban for Venous Thromboembolism Prophylaxis in Orthopaedic Trauma
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Unknown status
Technical summary
Registry record NCT04169269. Randomized; no masking; primary purpose prevention. Start 2020-01-13 (actual); primary completion 2020-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban
- Condition
- Deep Vein Thrombosis
- Condition
- Venous Thromboembolism
- Intervention (Drug)
- Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters
- Intervention (Drug)
- Rivaroxaban 10 milligram Oral Tablet
- Lead sponsor
- Florida Orthopaedic Institute
- Collaborator
- Orthopaedic Trauma Association
Record details
- Record id
cardio:ct-nct04169269- Content hash
d7af6e01ecb5062cc23b6bf32ff252c260bcf4432bbc66622d2a6e067c1fdc7c